{"disease":{"id":"medullary-thyroid-cancer-mtc","name":"medullary thyroid cancer mtc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07142005","title":"Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07048964","title":"A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT01856920","title":"QUILT-3.006 for Recurrent Medullary Thyroid Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT01945762","title":"Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT03072160","title":"Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}